Stephen Poor

Stephen Poor

Company: Novartis Institutes for Biomedical Research

Job title: Director External Opportunities & Translational Biomarkers


An Update & Analysis of the Macular Degeneration Complement Landscape 2:30 pm

Assessing the current status of complement therapeutics in clinical development What are the implications of month 24 Phase 3 data from APELLIS and Month 12 Phase 3 data from IVERIC for geographic atrophy treatment ( intravitreal C3 and C5 therapy)? What is the potential of gene therapy and systemic approaches in clinical development vs intravitreal…Read more

day: Track B - Day 1 PM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.